Type of Care
- Substance Use Treatment
- Treatment for co-occurring serious mental health illness/serious emotional disturbance and substance use disorders
Facility Operation (e.g., Private, Public)
- Private for-profit organization
Payment/Insurance/Funding Accepted
- Medicaid
- Private health insurance
- Cash or self-payment
Assessment/Pre-treatment
- Comprehensive mental health assessment
- Comprehensive substance use assessment
- Interim services for clients
Screening & Testing
- Drug or alcohol urine screening
- Screening for mental disorders
- Screening for substance use
Transitional Services
- Aftercare/continuing care
- Naloxone and overdose education
- Outcome follow-up after discharge
Ancillary Services
- Mental health services
Service Settings (e.g., Outpatient, Residential, Inpatient, etc.)
- Outpatient
- Outpatient methadone/buprenorphine or naltrexone treatment
- Regular outpatient treatment
Opioid Medications used in Treatment
- Buprenorphine used in Treatment
Tobacco/Screening Services
- Screening for tobacco use
Facility Smoking Policy
- Smoking not permitted
Gender Accepted
- Female
- Male
Opioid Medications used in Treatment
- Buprenorphine used in Treatment
- Naltrexone used in Treatment
External Opioid Medications Source
- Does not treat alcohol use disorder
Type of Opioid Treatment
- Buprenorphine maintenance
- Buprenorphine maintenance for predetermined time
- Prescribes buprenorphine
- Administers naltrexone
- Relapse prevention from naltrexone
Pharmacotherapies
- Acamprosate (Campral®)
- Buprenorphine sub-dermal implant (Probuphine®)
- Buprenorphine with naloxone (Ex. Suboxone®)
- Buprenorphine (extended-release, injectable, for example, Sublocade®)
- Naltrexone (oral)
- Naltrexone (extended-release, injectable naltrexone (Vivitrol®))
- Medications for psychiatric disorders
- Lofexidine
Treatment Approaches
- Relapse prevention
- Substance use counseling approach